In the DETO2X-AMI trial (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction), we compared supplemental oxygen with ambient air in normoxemic patients presenting with suspected myocardial infarction and found no significant survival benefit at 1 year. However, important secondary end points were not yet available. We now report the prespecified secondary end points cardiovascular death and the composite of all-cause death and hospitalization for heart failure.
D
espite progressively reduced mortality 1, 2 attributable to a combination of modern medical regimens and urgent revascularization, [3] [4] [5] ischemic heart disease is still a leading cause of death in the world. 6 The final infarct size remains strongly associated with the long-term risk of death or hospitalization for heart failure (HF) that occurs at a similar rate within the first year. 7 The rationale behind oxygen therapy in acute myocardial infarction (MI) is to improve the oxygen supply to the threatened myocardium, thereby decreasing myocardial injury and, in the long term, preventing the development of HF and thus improving prognosis. [8] [9] [10] However, high arterial oxygen tension may lead to negative cardiovascular effects on the myocardium at risk because of direct hyperoxemic vasoconstriction 11 and increased production of reactive oxygen species, 12, 13 and, consequently, increased infarct size 14 and the risk to develop HF. With the exception of statin therapy, 15, 16 little is known of the impact of pharmacotherapy on the risk of hospitalization for HF after an acute coronary syndrome.
In the DETO2X-AMI trial (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction), we found no significant survival benefit at 1 year of supplemental oxygen in comparison with ambient air in normoxemic patients presenting with suspected MI. 17 However, prespecified important secondary end points
were not yet available.
In the present study, we report long-term follow-up (median, 2.1 years) for all-cause mortality, and 1-year and long-term results for cardiovascular death and the composite of all-cause death and HF hospitalization, as well. The increased number of events in this report increases the power to detect an effect of treatment.
METHODS
The trial protocol and statistical analysis plan are available online. The data and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Study Design
The DETO2X-AMI trial was a multicenter, parallel-group, open-label, registry-based, randomized controlled trial 18 comparing routine supplemental oxygen therapy with ambient air in normoxemic patients with suspected MI. The trial used the national comprehensive SWEDEHEART system (Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies) 19 for patient enrollment and data collection. The study design, methods, and primary results have previously been described and published. 17, 20 The trial protocol was approved by the Ethical Review Board in Gothenburg and the Swedish Medical Products Agency. The trial sponsor was the Karolinska Institutet, Stockholm, Sweden. Trial and data management, monitoring, and statistical analyses were performed at the Uppsala Clinical Research Center at Uppsala University, Sweden. The study was conducted, and the article written, by the authors, who vouch for the data and all analyses, and for the fidelity of this report, the trial protocol, and statistical analysis plan, which are available online. The funding agencies had no access to the study data and no role in trial design, implementation, or reporting.
Patient Population
At first contact with the emergency medical service (ambulance and emergency department), coronary care unit, or catheterization laboratory of participating hospitals, patients were assessed for eligibility. Trial participants were required to be ≥30 years of age with symptoms typical for MI (defined as chest pain or dyspnea) for <6 hours, oxygen saturation of ≥90% on pulse oximetry, and either ECG changes indicating ischemia 21 or elevated cardiac troponin at the hospital (above the locally defined decision limit for MI). Only Swedish residents with a unique personal identification number were enrolled. Patients with ongoing oxygen therapy or cardiac arrest before enrollment were excluded.
Study Procedures
Patients fulfilling all inclusion criteria, and without exclusion criteria, were asked to provide oral consent followed by written confirmation within 24 hours. After oral consent, patients were randomly assigned to either oxygen therapy at 6 L/min for 6 to 12 hours delivered by open face mask or ambient air. Unrestricted one-to-one randomization following a computer-generated list was performed by means of
Clinical Perspective
What Is New?
• In the DETO2X-AMI trial (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction), we compared supplemental oxygen with ambient air in normoxemic patients presenting with suspected myocardial infarction and found no significant survival benefit at short term up to 1 year. In the present study, we report long-term follow-up (median, 2.1 years) for all-cause mortality, and 1-year and long-term results, as well, for cardiovascular death and the composite of all-cause death and heart failure hospitalization.
• Routine use of oxygen therapy was not found to reduce the composite of all-cause mortality and hospitalization for heart failure, or cardiovascular death within 1 year or during long-term follow-up.
What Are the Clinical Implications?
• Because oxygen therapy does not provide any clinically relevant long-term mortality or morbidity benefit in patients with suspected acute coronary syndrome without hypoxemia at baseline, it is time to change guideline recommendations and clinical practice. 
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an online randomization module within the SWEDEHEART registry. The study treatment was started on site immediately after randomization.
With the exception of the study intervention, all other treatments were left to the discretion of the treating physician. Oxygen saturation was documented at the beginning and at the end of the randomized treatment period. If considered clinically indicated, patients received oxygen therapy outside the protocol, which was reported separately.
End Points and Follow-Up
The prespecified secondary end point that this study focused on was time from randomization to the composite of allcause death or hospitalization for HF, censored at 365 days, in the intention-to-treat population and clinically relevant subgroups. Further secondary end points included all-cause death, rehospitalization with MI, hospitalization for HF, and composites of these end points, as well, assessed at 365 days and during long-term follow-up (median [range], 766 [365-1350] days). Furthermore, cardiovascular death was reported at the same time points.
Mortality data were obtained from the Swedish population registry, which includes the vital status of all Swedish residents with 99.5% completeness within a month. 22 Data on rehospitalization with MI were obtained from the SWEDEHEART registry, and defined according to International Classification of Diseases (ICD) codes I.21 and I.22. Data on hospitalization for HF were obtained from the Swedish inpatient registry, including all ICD codes from all admissions in Sweden, and defined as ICD code I.50. Data on cardiovascular death, defined as ICD codes I00 through I99 or unclassified, were obtained from the Swedish national cause-of-death registry.
The end of follow-up was December 30, 2016, 365 days after random assignment of the last patient. No central adjudication or study-specific patient follow-up was performed.
The study team and steering committee were blinded to treatment comparisons until locking of the database. Only authorized SWEDEHEART registry personnel had access to the randomization list. Accumulated data without treatment group information were available for monitoring the study progress throughout the trial.
Statistical Analysis
The sample-size calculations for the overall trial have been described previously. 17 Because of a lower than anticipated event rate in comparison with the original power calculation observed on automated data linkage with the population registry, the composite of death and hospitalization for HF was added as a key secondary end point, leaving the study design and primary end point unchanged. Data on hospitalization for HF were added to the analysis database from the Swedish inpatient registry in April 2018. Post hoc power was calculated given the event frequencies actually attained, for death, death or HF hospitalization, and death or HF hospitalization or MI rehospitalization at 365 days and during the total follow-up time of the trial.
The power for 1-year comparisons is computed for a 1-year risk modification showing a 20% relative risk reduction as in the original sample size calculation.
For the analysis of all follow-up time, the post hoc power was calculated based on the number of observed events, because different patients contributed with a different amount of patient-time.
The results were analyzed according to the intention-to-treat principle. Time to event within 365 days and during the entire follow-up with a maximum of 1357 days (median duration, 752 days) postrandomization is presented in Kaplan-Meier curves. Hazard ratios between treatment groups were calculated using a Cox proportional hazard model, adjusted for age in years (as a linear covariate on the log-hazard scale), and sex. Estimates of treatment differences are presented with 2-tailed 95% CIs and associated P values. A 2-tailed P value of <0.05 was considered statistically significant. Eleven prespecified subgroup analyses were performed using proportional hazards models with age and sex adjustment and formal tests for interaction.
Post hoc power was calculated using R v. 3.3.1. All other analyses were conducted with SAS v.9.4 (SAS Institute Inc).
RESULTS

Study Population
Thirty-five of Sweden's 69 hospitals with acute cardiac care facilities participated in the trial. Between April 13, 2013, and December 30, 2015, 6629 patients with suspected MI were enrolled and included in the intentionto-treat analysis.
Baseline characteristics, clinical presentation, and final diagnoses for all patients have been published in detail previously 17 (summarized and complemented with new data in Table 1 ). Overall, the treatment groups were well balanced without significant differences at baseline.
Procedural Data
Trial procedural data, medication, procedures, and complications during the hospitalization period have been reported in detail before 17 (summarized and complemented with new data in Table 2 ). In brief, at the time of randomization, the median oxygen saturation was 97.0%. Overall, 3311 patients were allocated to oxygen and 3318 patients were allocated to ambient air. The median duration of oxygen therapy was 11.64 hours, with a median oxygen saturation of 99.0% in patients assigned to oxygen and 97.0% in patients assigned to air at the end of the treatment period (P<0.001). Medication including HF treatment during the hospitalization period and at discharge, left ventricular ejection fraction assessed by echocardiography, and the peak level of high-sensitive cardiac troponin T (available in 5164 [78.0%] patients) showed no significant difference between the treatment arms (P=0.5) ( Table 2) . Furthermore, no significant difference between the groups was found concerning complications during the hospital stay (defined as reinfarction, new-onset atrial fibrillation, atrioventricular block II or III, cardiogenic shock, cardiac arrest, and death). (Figure 1, Table 3 ).
These findings were consistent across all prespecified subgroups (Figure 2 ). During the total follow-up time of the trial (median [range], 2.1 [1.0-3.7] years), the composite end point occurred in 372 patients (11.2%) in the oxygen group in comparison with 360 patients (10.8%) in the ambient-air group (HR, 1.02; 95% CI, 0.88-1.17; P=0.8) (Figure 3) .
The composite end point of all-cause death, rehospitalization with MI, or hospitalization for HF within 1 year occurred in 363 patients (11.0%) in the oxygen group and 350 patients (10.5%) in the ambient-air group (HR, 1.03; 95% CI, 0.89-1.19; P=0.7). The corresponding composite end point for the total follow-up time occurred in 518 patients (15.6%) in the oxygen group and 515 patients (15.5%) in the ambient-air group (HR, 1.00; 95% CI, 0.88-1.12; P=0.9).
Cardiovascular death within 1 year occurred in 121 patients (3.7%) assigned to oxygen versus 116 patients (3.5%) assigned to ambient air (HR, 1.03; 95% CI, 0.80-1.32; P=0.8). During long-term follow-up, cardiovascular death occurred in 173 patients (5.2%) in the oxygen group and 159 patients (4.8%) in the ambientair group (HR, 1.07; 95% CI, 0.87-1.33; P=0.5).
Post Hoc Estimation of Statistical Power
Statistical power to show a hazard modification of 0.8 based on the observed number of events within 1 year was 0.72 for the composite end point of death or HF hospitalization, and 0.84 for the composite of death, Plus-minus values are means±SD. There were no significant differences in baseline characteristics between the oxygen group and the ambient-air group except as otherwise noted. DETO2X-AMI indicates Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction; and Q1-Q3, the interval from the 25th to the 75th percentile. * P<0.05 for the comparison between the oxygen group and the ambientair group. 
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HF hospitalization, or MI rehospitalization. The power for a hazard modification of 0.8 based on the observed number of events during the total duration of the trial was 0.85 for the composite end point of death or HF hospitalization, and 0.95 for the composite of death, HF hospitalization, or MI rehospitalization.
DISCUSSION
In this pragmatic, investigator-initiated, registrybased randomized clinical trial of supplemental oxygen or ambient air in patients with suspected MI, routine oxygen therapy was not found to reduce the prespecified composite end point of all-cause death or hospitalization for HF within 1 year or during longterm follow-up. The neutral effect was consistent in all predefined subgroups. Even concerning cardiovascular mortality, no significant difference between the groups was detected. Previously, we reported the primary end point of the DETO2X-AMI study, all-cause death within 1 year, and found no significant survival benefit. Although recent European Society of Cardiology guidelines for patients with ST-segment-elevation myocardial infarction were changed based on these results, 5 and some experts already have called for a change of clinical practice, 23, 24 others have remained cautious because of a lower than expected event rate, requesting data on the effect on the development of HF, long-term follow-up, and specific data on cardiovascular mortality. Here, we report these end points with adequate statistical power and confirm our initial findings that routine oxygen therapy Figure 1 . Kaplan-Meier curves for the primary composite end point of all-cause death or hospitalization for heart failure up to 365 days. Kaplan-Meier curves are shown for the cumulative probability of primary composite end point of all-cause death or hospitalization for heart failure up to 365 days after randomization for patients assigned to oxygen or ambient air. ORIGINAL RESEARCH ARTICLE seems unnecessary in the majority of normoxemic patients with suspected MI. Our findings were supported in a recent meta-analysis including data from all available randomized controlled trials examining the role of supplemental oxygen in suspected MI. 25 Moreover, we recently reported no effect of routine oxygen therapy on percutaneous coronary intervention-related outcomes in patients with ST-segment-elevation myocardial infarction, 26 and the systemic inflammatory response to acute MI. 27 Thus, we can conclude that oxygen therapy appears to be unnecessary for patients without hypoxemia but does not seem to cause harm, which has been feared based on a single-center clinical trial in patients with ST-segment-elevation myocardial infarction 14 and a recent meta-analysis including a broad group of patients and diseases. 28 Our overall findings suggest that the cardiovascular effect of supplemental oxygen in a moderate dose for a relatively short time is very limited if existent at all. A similar observation was reported from a recent multicenter randomized controlled trial in the United Kingdom in 8003 patients with acute stroke. Routine prophylactic low-dose oxygen therapy did not improve outcome among patients who were not hypoxemic at baseline, regardless of whether oxygen was given continuously for 72 hours or at night only. This applied to the primary end point of 90-day functional outcome and secondary outcome measures, including early neurological recovery, mortality, disability, independence in basic and extended activities of daily living, and quality of life. 29 Notwithstanding, a potential dose-dependent toxicity of supplemental oxygen remains. We designed our study to mimic current clinical practice in patients with suspected MI without hypoxemia at baseline. By using a moderate dose of oxygen combined with a lower limit of oxygen saturation of ≥90%, we optimized oxygenation and reduced the risk of inadvertent hyperoxemia and potential harm. However, in some other clinical scenarios-for example, cardiac arrest with the need for cardiopulmonary resuscitation-high-flow oxygenation is still common practice without sound evidence from large enough trials, 30 which needs to be clarified in the future. 31 General limitations to our trial and the study design have been described in detail previously. 17, 20 A limitation to the statistical power of the primary end point within 1 year was the lower than expected mortality rate. Various reasons contributed, most importantly the exclusion of hypoxemic patients and the obligatory informed consent procedure required for Hazard ratios are shown for the primary composite end point of all-cause death or hospitalization for heart failure within 365 days after randomization. AMI, acute myocardial infarction; CKD, chronic kidney disease; HR, hazard ratio; ITT, intention-to-treat; LBBB, left bundle-branch block; MI, myocardial infarction; NSTEMI, non-ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; and PP, per-protocol.
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enrollment that many times makes it challenging to recruit frailer patients. The lower than expected event rate was discussed during the trial, without access to treatment comparisons, and the composite of death or hospitalization for HF was added as the main secondary outcome variable. Although the conclusions from the HF composites should be drawn from the CIs and P values, post hoc power calculations presented here now show good statistical certainty, in particular during long-term follow-up. There was no central adjudication of events. However, the ICD codes in the Swedish national inpatient registry have a high validity with a positive predictive value, in general, of 85% to 95%. 32 In conclusion, supplemental oxygen in normoxemic patients with suspected MI was not found to reduce the composite of all-cause death or hospitalization for HF within 1 year or during long-term follow-up. Because oxygen therapy does not provide any clinically relevant long-term mortality or morbidity benefit in patients with suspected acute coronary syndrome without hypoxemia at baseline, it is time to change guideline recommendations and clinical practice. Figure 3 . Kaplan-Meier curves for the composite end point of all-cause death or hospitalization for heart failure for the total follow-up time of the trial. Kaplan-Meier curves are shown for the cumulative probability of the composite end point of all-cause death or hospitalization for heart failure for the total follow-up time of the trial (median duration, 752 days) with a maximum of 1357 days after randomization for patients assigned to oxygen or ambient air (post hoc analysis).
ARTICLE INFORMATION
